Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH-10D7ICG is a **fluorescent probe** created by chemically conjugating the near-infrared dye **indocyanine green (ICG)** to the monoclonal antibody **10D7**, which specifically targets the CUB-domain-containing protein 1 (CDCP1), a receptor overexpressed on ovarian cancer cells. This agent is developed to enable **tumor-selective fluorescence imaging**, enhancing the visualization of ovarian cancer lesions during surgery. Preclinical studies have shown intravenous administration of CH-10D7ICG allows preferential accumulation in ovarian cancer xenografts, supporting its potential use in **fluorescence-guided surgery for ovarian cancer**[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CH-10D7ICG.